Renal excretion of meta-iodobenzylguanidine after therapeutic doses in cancer patients and its relation to dose and creatinine clearance.
Iodine-131 radioiodinated meta-iodobenzylguanidine (131I-MIBG) is used for diagnostic scintigraphy and radionuclide therapy of neural crest-derived tumours. In higher doses (up to 80 mg), non-radioactive MIBG is now evaluated for palliation in carcinoid patients. After administration of therapeutic doses of 131I-MIBG (3.7-7.4 GBq, 1.7-5.8 mg MIBG) to patients aged 2-73 years, 53 +/- 8.8%, 69 +/- 7.8% and 83 +/- 7.0% of the dose was cumulatively excreted as MIBG in the urine after 24, 48 and 72 h, respectively. Within the MIBG dose range of 1.7-80.0 mg, a linear relationship was found between the excretion rate over the first 24 h (mg per 24 h) and the dose. In adults, the MIBG excretion rate over the first 24 h (% of dose per 24 h) was shown to be only partially related to the glomerular filtration rate (GFR).
D019797:3-Iodobenzylguanidine; D000293:Adolescent; D000310:Adrenal Gland Neoplasms / Q000532:radiotherapy; D000328:Adult; D000367:Age Factors; D000368:Aged; D002276:Carcinoid Tumor / Q000532:radiotherapy; D002648:Child; D002675:Child, Preschool; D003404:Creatinine / Q000378:metabolism; D006801:Humans; D007457:Iodine Radioisotopes / Q000493:pharmacokinetics* / Q000627:therapeutic use* / Q000652:urine; D007462:Iodobenzenes / Q000493:pharmacokinetics* / Q000627:therapeutic use* / Q000652:urine; D008657:Metabolic Clearance Rate; D008875:Middle Aged; D009369:Neoplasms / Q000532:radiotherapy*; D009447:Neuroblastoma / Q000532:radiotherapy; D010673:Pheochromocytoma / Q000532:radiotherapy
D007457:Iodine Radioisotopes; D007462:Iodobenzenes; D019797:3-Iodobenzylguanidine; D003404:Creatinine